Compare Abeona Therapeutics Inc (ABEO) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Financial Select Sector SPDR Fund — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Financial Select Sector SPDR Fund trades at $55.23. Which is the better fit depends on your goals.
| ABEO | XLF | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | — |
52-Week High | $7.23 | $56.41 |
52-Week Low | $4.17 | $47.80 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
XLF trades at $56.15, up 0.95% with strong technical momentum as moving averages signal bullish alignment. The ETF faces pivotal Q2 earnings season with major bank components reporting, while regulatory developments and potential rate hikes create both opportunities and headwinds. Recent Federal Reserve stress test results have enabled increased dividends, with XLF announcing a $0.19 dividend for H1-2026.
The financial sector ETF shows technical strength but faces fundamental tests from earnings season and regulatory uncertainty. Upside potential exists from dividend growth and potential rate hike benefits, while risks include AI cybersecurity threats and election-driven market volatility that could pressure financial stocks in H2 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
